CanSense
Generated by Meeveem AI
"Detecting bowel cancer early with a single non-invasive blood test"
Swansea
•11 - 50 Employees
•Diagnostics
About CanSense
CanSense develops a pioneering blood test for early detection of bowel cancer, the third most common cancer globally. Using laser spectroscopy combined with artificial intelligence, the technology delivers a fast, accurate diagnostic tool that identifies cancer and pre-cancerous polyps from a single blood sample, eliminating the need for invasive colonoscopies. The test benefits patients through earlier intervention when treatment is most effective, supports clinicians with reliable triage decisions, and helps pharmaceutical companies enhance clinical trials. With only 15 percent of colorectal cancers currently detected early, CanSense aims to reshape diagnostic pathways and improve survival rates worldwide.
15
Team Members
2018
Founded
Diagnostics
Sector
Hybrid
Work Environment
Our Vision
A world where bowel cancer is detected at its earliest stages, dramatically improving survival rates and transforming patient outcomes globally.
Our Mission
At CanSense, our mission is to transform lives through the early detection of cancer by delivering a dependable, accurate and non-invasive blood test.